Braskem S.A.
NYSE:BAKChemicals
-$0.40 today
- Market cap
- $343.37M
- Beta
- 0.67
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$11.45
Volume 3.32M
Average 2.97M
BAK EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Braskem S.A.NYSE: BAK
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q1 FY2026 EBITDA of R$3.46B rose 6.3% year over year, behind the +2564.8% change in trailing-twelve-month EBITDA. Sequentially, it rose 62.9% from the prior quarter. Over 3 fiscal years it compounded at -57.3% a year.
Context
- EBITDA amounted to 0.9% of revenue in FY2025, down 2.6 pp from a year earlier.
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of R$11.34B (+1696.0%) for the fiscal year ending Dec 2026, a step up from the -76.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- R$3.46B+62.9% QoQ
- Last fiscal yearDec 2025
- R$631.35M-76.6% YoY
- LTMMar 2026
- R$6.93B+2564.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.3% | +184.1% | +177.8 pp |
| 1 year | -76.6% | +1696.0% | +1772.6 pp |
| 3-year CAGR | -57.3% | +134.7% | +192.0 pp |
| 5-year CAGR | +66.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
BRL · from the income statement
- Latest · FY2025
- 631.35M BRL
- Year-over-year change
- -76.6%
- 4-year CAGR
- -60.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 631.35M | -76.6% |
| FY2024 | 2024-12-31 | 2.7B | -17.4% |
| FY2023 | 2023-12-31 | 3.26B | -59.7% |
| FY2022 | 2022-12-31 | 8.11B | -68.0% |
| FY2021 | 2021-12-31 | 25.33B | — |
EBITDA vs competitors
How BAK compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2564.8% is the highest of 11, against a peer median of +15.6%.
- EBITDA amounts to 10.4% of revenue for BAK, versus a peer median of 26.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | R$6.93B BRL | +2564.8% | -57.3% | 10.4% | |
| LTM Mar 2026 | $466.81M USD | +8.6% | -1.5% | 37.8% | |
| LTM Mar 2026 | $235.69M USD | +22.6% | -19.4% | 36.6% | |
| LTM Mar 2026 | $171.7M USD | +23.7% | -2.3% | 12.0% | |
| LTM Mar 2026 | $151.69M USD | +37.7% | -13.1% | 18.5% | |
| LTM Mar 2026 | $139.93M USD | -27.5% | -10.3% | 6.0% | |
| LTM Apr 2026 | $118.71M USD | +6.6% | +14.2% | 18.1% | |
| LTM Mar 2026 | $79M USD | +248.7% | — | 33.5% | |
| LTM Mar 2026 | -CA$38.33M CAD | +44.6% | — | — | |
CNLCollective Mining Ltd. | LTM Mar 2026 | -$43.45M USD | -12.6% | — | — |
| LTM Mar 2026 | -$170.61M USD | -417.3% | — | 633.6% | |
| Peer median (excluding BAK) | — | +15.6% | -6.3% | 26.0% | |
Competitors are the stored peer set for BAK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 105.63B | 96.52B | 70.57B | 77.41B | 69.33B |
| Cost of Revenue | 73.57B | 85.16B | 67.55B | 71.41B | 67.8B |
| Gross Profit | 32.06B | 11.36B | 3.02B | 6B | 1.53B |
| Gross Margin | 30.3% | 11.8% | 4.3% | 7.7% | 2.2% |
| Research & Development | 297M | 374M | 383M | 463M | 450.96M |
| Selling, General & Admin | 4.58B | 4.87B | 4.39B | 4.63B | 4.68B |
| Operating Expenses | 4.88B | 5.25B | 4.77B | 4.99B | 5.48B |
| Depreciation & Amortization | 4.18B | 4.73B | 5.21B | 3.75B | 4.58B |
| EBITDA | 25.33B | 8.11B | 3.26B | 2.7B | 631.35M |
| EBITDA Margin | 24.0% | 8.4% | 4.6% | 3.5% | 0.9% |
| Operating Income | 27.18B | 6.11B | (1.75B) | 1.01B | (3.95B) |
| Operating Margin | 25.7% | 6.3% | -2.5% | 1.3% | -5.7% |
| Interest Income | 440M | 1.05B | 873M | 1.26B | 711.74M |
| Interest Expense | 3.19B | 3.33B | 4.78B | 5.44B | 5.82B |
| Other Income / Expenses | (9.22B) | (6.07B) | (4.44B) | (18.75B) | 1.16B |
| Income Before Tax | 17.96B | 47M | (6.19B) | (17.73B) | (2.79B) |
| Pre-Tax Margin | 17.0% | 0.0% | -8.8% | -22.9% | -4.0% |
| Income Tax Expense | 4B | 868M | (1.3B) | (5.68B) | 7.96B |
| Net Income | 13.99B | (336M) | (4.58B) | (11.32B) | (9.69B) |
| Net Margin | 13.2% | -0.3% | -6.5% | -14.6% | -14.0% |
| EPS (Basic) | 35.12 | (2.06) | (11.50) | (28.40) | (24.32) |
| EPS (Diluted) | 35.08 | (2.06) | (11.50) | (28.40) | (24.32) |
| Weighted Avg Shares | 398.11M | 398.24M | 398.35M | 398.6M | 398.6M |
| Weighted Avg Shares (Diluted) | 398.61M | 398.6M | 398.35M | 398.6M | 398.6M |
Braskem S.A.
NYSE:BAK
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.